{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"1.6","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the period from study entry until disease progression, death, or the last date of contact. Progression was based on RECIST 1.1. RECIST 1.1 defines progressive disease as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions or unequivocal progression of non-target lesions is also considered progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment","id":"OG000","title":"Ixabepilone"}],"paramType":"MEDIAN","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"From study entry to disease progression, death or date of last contact, whichever occurs first, up to 5 years of follow-up.","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}